Skip to main content

Table 6 Potential predictors of MTX intolerance (MISS ≥ 6)

From: Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

  MISS intolerance
  OR (95 % CI)a p-value
Male 0,70 (0,22; 2,22) 0,546
Age at onset (by 10 yrs) 1,61 (0,51; 5,02) 0,416
Age at MTX start (by 10 yrs) 1,46 (0,48; 4,47) 0,505
Interval from onset to MTX start (by 10 months) 0,41 (0,10; 1,58) 0,194
Uveitis before MTX treatment 0,87 (0,21; 3,67) 0,853
ANA positive 1,49 (0,51; 4,37) 0,465
Active joints (by 10 joints) 1,01 (0,55; 1,84) 0,979
Joints with limitation of motion (by10 joints) 1,12 (0,63; 1,98) 0,695
Physician global assessment of disease activity (by 10 mm) 1,22 (0,87; 1,69) 0,245
Parent/patient global assessment of well-being (by 10 mm) 0,88 (0,68; 1,14) 0,328
FW (by 10 mm/h) 1,26 (0,95; 1,67) 0,111
CRP (by 10 mg/l) 1,09 (0,89; 1,34) 0,409
CHAQ 0,30 (0,08; 1,17) 0,083
JADAS 71(á 10 points) 1,12 (0,68; 1,82) 0,659
Parenteral form of methotrexate 2,44 (0,56; 10,65) 0,236
Initial MTX dose (mg/m2) 1,15 (0,94; 1,40) 0,181
Polyarticular form of JIA 1,43 (0,36; 5,78) 0,612
  1. aOR = odds ratio, 95 % IS = 95 % confidence interval